Want to see AZTR full AI Analyst Report?
AZTR Stock Chart & Stats
$0.30
-$0.02(-5.17%)
At close: 4:00 PM EST
$0.30
-$0.02(-5.17%)
Day’s Range― - ―
52-Week Range$0.10 - $1.59
Previous CloseN/A
Volume201.32K
Average Volume (3M)169.78K
Market Cap
$2.25M
Enterprise Value-$5.98
Total Cash (Recent Filing)$10.05M
Total Debt (Recent Filing)$343.33K
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 17, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding16,192,438
10 Day Avg. Volume152,326
30 Day Avg. Volume169,784
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Shift To Cosmetics & Biotech ToolsAzitra broadened its addressable markets by redirecting resources to ATR-COSF (a recombinant filaggrin cosmetic program) and in-licensed microbial engineering for biotech tools. These moves create nearer-term commercial pathways and diversify reliance on a single clinical asset, improving long-term revenue optionality and partnership appeal.
Recent Financing Improves Near-term RunwayThe $10.5M financing extends operational runway to advance product optimization, ex vivo studies and a planned ATR-COSF clinical study into late 2026. Securing capital for milestone delivery materially lowers immediate solvency risk and increases the chance of achieving de-risking events that enable partnerships or follow-on commercial steps.
Improved Capitalization And Modest LeverageReported improvements in capitalization and modest debt reduce near-term balance-sheet pressure and provide flexibility to fund development or licensing discussions. Lower leverage compared with earlier periods means less immediate insolvency risk and a stronger platform to negotiate partnerships or non-dilutive funding.
Bears Say
Revenue Collapsed To Zero In 2025/TTMThe drop to zero reported revenue demonstrates a lack of recurring commercial scale and weak product monetization. Over a multi-month horizon this undermines self-funded growth, forces reliance on external capital, and signals execution or market-fit issues that materially raise the bar for sustainable, durable revenue generation.
Persistent Cash Burn And Deteriorating Cash FlowSustained negative operating and free cash flow means the business is consuming cash rather than generating it, creating repeated need for financing. This structural cash burn constrains R&D and commercialization investments, increases dilution risk, and reduces the company's ability to execute on multi-year development plans without external funding.
Authorized Share Expansion Enables DilutionA large expansion of authorized shares creates a structural pathway for significant equity issuance to raise capital. Given ongoing losses and cash needs, management has the capacity to dilute existing holders, which can materially weaken shareholder economics and increase financing reliance over the coming months.
Azitra Inc News
AZTR FAQ
What was Azitra Inc’s price range in the past 12 months?
Azitra Inc lowest stock price was $0.10 and its highest was $1.59 in the past 12 months.
What is Azitra Inc’s market cap?
Azitra Inc’s market cap is $2.25M.
When is Azitra Inc’s upcoming earnings report date?
Azitra Inc’s upcoming earnings report date is Aug 17, 2026 which is in 27 days.
How were Azitra Inc’s earnings last quarter?
Azitra Inc released its earnings results on May 13, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.24.
Is Azitra Inc overvalued?
According to Wall Street analysts Azitra Inc’s price is currently Undervalued.
Does Azitra Inc pay dividends?
Azitra Inc does not currently pay dividends.
What is Azitra Inc’s EPS estimate?
Azitra Inc’s EPS estimate is -0.12.
How many shares outstanding does Azitra Inc have?
Azitra Inc has 16,192,438 shares outstanding.
What happened to Azitra Inc’s price movement after its last earnings report?
Azitra Inc reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -1.818%.
Which hedge fund is a major shareholder of Azitra Inc?
Currently, no hedge funds are holding shares in AZTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Azitra Inc
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
AZTR Stock 12 Month Forecast
Average Price Target
$1.00
▲(233.33% Upside)
Technical Analysis
Ownership Overview
27.62% Insiders
0.47% Mutual Funds
0.14% Other Institutional Investors
71.76% Public Companies and
Individual Investors